Amgen, Inc.’s AMGN novel investigational KRAS inhibitor for solid tumor, AMG 510, showed anti-tumor activity with no dose-limiting toxicities in a larger group of lung cancer patients.
Amgen presented new data from a phase I study evaluating AMG 510 in patients with heavily pretreated KRAS G12C-mutated solid tumors at IASLC 2019 World Conference on Lung Cancer (WCLC).
Amgen shares have risen 6.7% this year so far compared with 2.4% decrease registered by the industry during this period.
In June, Amgen presented encouraging early clinical data on AMG-510 at the annual meeting of the American Society of Clinical Oncology (ASCO). In the phase I study, AMG 510, when given as a monotherapy, showed encouraging anti-tumor activity in patients with locally-advanced or metastatic KRASG12C mutant solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
The follow-up data presented at WCLC was from a larger group of NSCLC patients. The data showed that 54% of the 13 evaluable NSCLC patients, given a high dose of 960 mg once daily, experienced a partial response. Also, 46% of the patients achieved stable disease for a disease control rate of 100% at the target dose.
We remind investors that in July, along with the second-quarter results, Amgen said that AMG-510 showed responses in patients with colorectal and appendiceal cancer. Back then, Amgen had said that it is enrolling patients in a NSCLC cohort in combination with a PD-1 inhibitor. It plans to initiate a registration enabling phase II study soon.
KRAS gene has been a target of active exploration in cancer research and is particularly common in solid tumors. Amgen believes that AMG 510 has the potential to be developed into a successful targeted therapy to treat patients with the KRASG12C mutation due to its high selectivity for this mutation.
AMG510 enjoys orphan drugs status from the FDA for KRASG12C-positive NSCLC and colorectal cancers.
Another company, Mirati Therapeutics Inc MRTX also has a candidate, MRTX849, which targets the KRAS G12C mutation.
Amgen currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some other top-ranked biotech stocks include Alexion ALXN and Biogen BIIB. Both carry a Zacks Rank #2.
Shares of Alexion have risen 6.6% this year so far. Earnings estimates for 2019 and 2020 have risen 4.7% and 2.3%, respectively over the past 60 days.
Earnings estimates for Biogen for 2019 and 2020 have risen 9.1% and 3.6%, respectively over the past 60 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
Biogen Inc. (BIIB) : Free Stock Analysis Report
Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research